HOME Research Insight Partnerships, Collaborations, Agreements, and Joint Ventures Accounted for the Largest Share of the Overall Growth Strategies Adopted by Players to Sustain their Market Growth in the Cellular Health Screening/Health Testing Market



Partnerships, Collaborations, Agreements, and Joint Ventures Accounted for the Largest Share of the Overall Growth Strategies Adopted by Players to Sustain their Market Growth in the Cellular Health Screening/Health Testing Market


The global cellular health screening market is expected to reach USD 3.42 Billion by 2022 from USD 2.12 Billion in 2017, at a CAGR of 10.0% during the forecast period. The increasing adoption of telomere performance programs for leading a healthy life; growing focus on increasing healthy life expectancy (HALE); increasing government focus towards preventive healthcare; rising geriatric population and the subsequent growth in the need for cellular health screening; increasing research activities; growing adoption of the direct-to-consumer approach for the availability of kits; and increasing burden of chronic diseases are the major factors that are expected to drive the growth of the cellular health screening market.

Partnerships, collaborations, agreements, and joint ventures accounted for the largest share of the overall growth strategies adopted by players to sustain their market growth.

The global cellular health screening market is highly competitive with several big and small players. Prominent players in the market include Genova Diagnostics (U.S.), Telomere Diagnostics (U.S.), Life Length (Spain), Quest Diagnostics (U.S.), Repeat Diagnostics (Canada), SpectraCell Laboratories (U.S.), Zimetry LLC (U.S.), Cell Science Systems (U.S.), Titanovo, Inc. (U.S.), Segterra, Inc. (U.S.), LabCorp Holdings (U.S.), BioReference Laboratories (U.S.), Immundiagnostik AG (Germany), DNA Labs (India), and Cleveland HeartLab, Inc. (U.S.).

In 2016, Telomere Diagnostics accounted for the largest share of the cellular health screening market. With its large presence and expertise in telomere testing, the company has maintained its leadership position in the market. Telomere majorly focuses on developing new products that offer innovative solutions to help people test their cellular health and take preventive and therapeutic measures as required. For instance, in 2016, the company launched the TeloYears genetic test, which helps track the cellular age of an individual based on the telomere length.

Life Length has maintained its strong market position by dominating the European telomere testing market. The company has adopted various strategies, such as partnerships, agreements, and joint ventures, to sustain its growth in the telomere testing market. For instance, the company partnered with Eastern Biotech & Life Sciences (Dubai) in 2016 and Freiburg Medical Laboratory Middle East (FML) (Dubai) in 2014 to expand its business in the Middle East. Also, in 2014, the company signed an agreement with Invivo Clinical (U.K.) to offer its telomere analysis technology (TAT) in the U.K.

Related Reports:

Cellular Health Screening/Health Testing Market by Type (Single (Telomere, Oxidative Stress, Inflammation, Heavy Metal), Multitest), Sample (Blood, Saliva, Serum, Urine), Collection Site (Home, Office, Hospital, Diagnostic Labs), and Region - Global Forecast to 2022

Contact:
Mr. Rohan
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports